Search

DexCom Inc

Fermé

SecteurSoins de santé

91.02 -1.18

Résumé

Variation du prix de l'action

24h

Actuel

Min

90.86

Max

92.56

Chiffres clés

By Trading Economics

Revenu

50M

249M

Ventes

117M

1.3B

P/E

Moyenne du Secteur

35.083

57.371

BPA

0.7

Marge bénéficiaire

19.039

Employés

11,000

EBITDA

52M

389M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+0.97% upside

Dividendes

By Acuity

Prochains Résultats

29 oct. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

5.2B

33B

Ouverture précédente

92.2

Clôture précédente

91.02

DexCom Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 août 2026, 19:36 UTC

Social Media

Dexcom Inc shares are higher as $1.6 million in call options signals bullish investor sentiment. The stock has recovered from earlier session lows.

20 août 2026, 19:36 UTC

Dexcom Inc shares are higher today, continuing a three-session upward trend. The stock has fluctuated within a narrow range during regular trading hours.

19 août 2026, 19:41 UTC

Dexcom Inc shares are higher Wednesday, pulling back from an early peak. The stock is trading with unusually high volume and remains above its 20-day moving average.

18 août 2026, 19:16 UTC

Dexcom Inc shares are higher today, reflecting positive market sentiment despite no specific news. The stock remains above its 20-day moving average.

17 août 2026, 19:46 UTC

Dexcom Inc's shares are lower today, continuing a decline since Friday's close. No specific news has been identified to explain the price movement.

14 août 2026, 19:16 UTC

Dexcom Inc shares are lower today, continuing a decline since Thursday's close amid broader market caution following an unexpected drop in U.S. retail sales.

13 août 2026, 19:26 UTC

Dexcom Inc shares are higher today, despite an earlier pullback. The stock's advance contrasts with a broader market decline since the session's start.

12 août 2026, 19:36 UTC

Dexcom Inc shares are higher amid broader market optimism following inflation data. The core Consumer Price Index showed a modest increase, aligning with forecasts.

11 août 2026, 23:26 UTC

Dexcom Inc shares are trading lower in after-market hours. Broader market trends and cautious investor sentiment may be influencing this price movement.

10 août 2026, 20:02 UTC

Dexcom Inc shares are higher today, continuing an upward trend since Friday. The move occurs amid recent labor market data influencing investor sentiment.

7 août 2026, 23:46 UTC

Dexcom Inc shares are higher in after-market hours, continuing recent positive momentum. The stock remains well above its 20-day moving average.

5 août 2026, 19:51 UTC

News

Dexcom shares are declining amid negative sentiment in the insulin sector following Podd's revenue growth forecast cut. Broader economic data also influences cautious market sentiment.

4 août 2026, 19:56 UTC

Dexcom Inc. shares are lower today, pulling back after reaching a session high. The broader market benefits from a significant decline in crude oil prices.

3 août 2026, 20:02 UTC

News
Social Media

Dexcom Inc. shares are higher following strong Q2 results and raised revenue guidance to $5.22 billion. Canaccord increased its price target to $90.

31 juil. 2026, 20:04 UTC

News
Social Media

Dexcom Inc. shares are higher following analyst upgrades and strong earnings, with second-quarter revenue of $1.31 billion exceeding expectations and guidance raised to $5.22 billion.

30 juil. 2026, 23:51 UTC

News
Social Media

Dexcom reported second-quarter revenue of $1.308 billion and adjusted EPS of $0.70, raising its fiscal year 2026 revenue guidance, with shares trading higher in after-market hours.

29 juil. 2026, 23:41 UTC

Dexcom Inc is trading higher in after-market hours, supported by overall market strength. The asset remains above its 20-day moving average.

28 juil. 2026, 20:06 UTC

News

Dexcom shares rise after UBS initiated coverage with a Buy rating. The stock is advancing since Monday's close of $73.37 amid positive sentiment in the Health Care Equipment sector.

27 juil. 2026, 19:06 UTC

News

Dexcom Inc. gains Health Canada approval for its Dexcom G7 continuous glucose monitoring system, boosting marketability and user adoption amid positive analyst sentiment.

24 juil. 2026, 15:22 UTC

Dexcom Inc's shares are higher today, driven by gains in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

22 juil. 2026, 20:01 UTC

Dexcom Inc. shares are lower today, continuing a decline since Tuesday. Earlier, the stock briefly rose before pulling back.

21 juil. 2026, 19:26 UTC

Dexcom Inc is trading lower, continuing a trend of three consecutive declines. The stock reached a session low earlier today before a slight recovery.

20 juil. 2026, 19:22 UTC

Dexcom Inc shares are lower amid broader market declines and rising Treasury yields. The stock remains near the upper end of its one-month trading range.

Comparaison

Variation de prix

DexCom Inc prévision

Objectif de Prix

By TipRanks

0.97% hausse

Prévisions sur 12 Mois

Moyen 93.24 USD  0.97%

Haut 105 USD

Bas 82 USD

Basé sur 19 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

19 ratings

18

Achat

1

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat